Cargando…

Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer

PURPOSE: The formulation of topical ophthalmic products with appropriate therapeutic effect and patient compliance is a major challenge. To increase the efficiency of the ocular delivery of the drug, the enhancement of water solubility and the contact time of the drug on the surface of the cornea ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Bíró, Tivadar, Horvát, Gabriella, Budai-Szűcs, Mária, Csányi, Erzsébet, Urbán, Edit, Facskó, Andrea, Szabó-Révész, Piroska, Csóka, Ildikó, Aigner, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101011/
https://www.ncbi.nlm.nih.gov/pubmed/30147300
http://dx.doi.org/10.2147/DDDT.S165693
_version_ 1783348975165767680
author Bíró, Tivadar
Horvát, Gabriella
Budai-Szűcs, Mária
Csányi, Erzsébet
Urbán, Edit
Facskó, Andrea
Szabó-Révész, Piroska
Csóka, Ildikó
Aigner, Zoltán
author_facet Bíró, Tivadar
Horvát, Gabriella
Budai-Szűcs, Mária
Csányi, Erzsébet
Urbán, Edit
Facskó, Andrea
Szabó-Révész, Piroska
Csóka, Ildikó
Aigner, Zoltán
author_sort Bíró, Tivadar
collection PubMed
description PURPOSE: The formulation of topical ophthalmic products with appropriate therapeutic effect and patient compliance is a major challenge. To increase the efficiency of the ocular delivery of the drug, the enhancement of water solubility and the contact time of the drug on the surface of the cornea are necessary. In this work, prednisolone (PR)-containing eye drops were formulated with antimicrobial, mucoadhesive biopolymer and PR–cyclodextrin inclusion complex. This approach can be used for the development of innovative ophthalmic formulations. MATERIALS AND METHODS: After adjusting the optimal physiological parameters, the amount of the required cyclodextrin for the highest penetration of PR was determined by dialysis membrane diffusion study. The viscosity, surface tension and mucoadhesion of the eye drops were measured. The microbiological effectiveness of zinc-hyaluronate (ZnHA) was investigated by a standard method of the European Pharmacopoeia. RESULTS: In this case, no significant difference of surface tension was measured in products with different amounts of cyclodextrin. According to the results of the tensile test, ZnHA as a mucoadhesive biopolymer improves the mucoadhesion of ophthalmic products. The antimicrobial stability of formulations preserved by ZnHA meets requirement B of the European Pharmacopoeia. CONCLUSION: It can be stated that the innovative PR-containing compositions are suitable for producing mucoadhesive, properly preserved aqueous ophthalmic solutions with increased bioavailability attributes.
format Online
Article
Text
id pubmed-6101011
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61010112018-08-24 Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer Bíró, Tivadar Horvát, Gabriella Budai-Szűcs, Mária Csányi, Erzsébet Urbán, Edit Facskó, Andrea Szabó-Révész, Piroska Csóka, Ildikó Aigner, Zoltán Drug Des Devel Ther Original Research PURPOSE: The formulation of topical ophthalmic products with appropriate therapeutic effect and patient compliance is a major challenge. To increase the efficiency of the ocular delivery of the drug, the enhancement of water solubility and the contact time of the drug on the surface of the cornea are necessary. In this work, prednisolone (PR)-containing eye drops were formulated with antimicrobial, mucoadhesive biopolymer and PR–cyclodextrin inclusion complex. This approach can be used for the development of innovative ophthalmic formulations. MATERIALS AND METHODS: After adjusting the optimal physiological parameters, the amount of the required cyclodextrin for the highest penetration of PR was determined by dialysis membrane diffusion study. The viscosity, surface tension and mucoadhesion of the eye drops were measured. The microbiological effectiveness of zinc-hyaluronate (ZnHA) was investigated by a standard method of the European Pharmacopoeia. RESULTS: In this case, no significant difference of surface tension was measured in products with different amounts of cyclodextrin. According to the results of the tensile test, ZnHA as a mucoadhesive biopolymer improves the mucoadhesion of ophthalmic products. The antimicrobial stability of formulations preserved by ZnHA meets requirement B of the European Pharmacopoeia. CONCLUSION: It can be stated that the innovative PR-containing compositions are suitable for producing mucoadhesive, properly preserved aqueous ophthalmic solutions with increased bioavailability attributes. Dove Medical Press 2018-08-15 /pmc/articles/PMC6101011/ /pubmed/30147300 http://dx.doi.org/10.2147/DDDT.S165693 Text en © 2018 Bíró et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Bíró, Tivadar
Horvát, Gabriella
Budai-Szűcs, Mária
Csányi, Erzsébet
Urbán, Edit
Facskó, Andrea
Szabó-Révész, Piroska
Csóka, Ildikó
Aigner, Zoltán
Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer
title Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer
title_full Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer
title_fullStr Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer
title_full_unstemmed Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer
title_short Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer
title_sort development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101011/
https://www.ncbi.nlm.nih.gov/pubmed/30147300
http://dx.doi.org/10.2147/DDDT.S165693
work_keys_str_mv AT birotivadar developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT horvatgabriella developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT budaiszucsmaria developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT csanyierzsebet developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT urbanedit developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT facskoandrea developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT szaboreveszpiroska developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT csokaildiko developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer
AT aignerzoltan developmentofprednisolonecontainingeyedropformulationsbycyclodextrincomplexationandantimicrobialmucoadhesivebiopolymer